AZN Jan 2026 75.000 put
| Previous Close | 5.60 |
| Open | 5.60 |
| Bid | 6.20 |
| Ask | 6.35 |
| Strike | 75.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 5.60 - 5.60 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 485 |
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Business WireAIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
WILMINGTON, Del., October 07, 2024--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.1 The trial included patients with intermittent or mild persistent asthma, including those on short-acting
ReutersAstraZeneca signs $1.92 billion licencing deal with HK-listed CSPC
Apart from the aforementioned milestone and royalty payment, Hong Kong-based CSPC will also get an upfront payment of $100 million as part of the deal. CSPC will develop an early-stage, novel small molecule Lipoprotein (a) disruptor, which could offer benefits to patients with high levels of "bad cholesterol", AstraZeneca said. AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp(a) disruptor, with the aim to develop it as a lipid-lowering therapy.
